It would however be particularly intriguing for future studies to analyze if angiosarcomas arising in patients with Sturge-Weber syndrome are found to frequently harbor activating mutations in GNAQ. If this were the case, it could have therapeutic consequences, as approaches targeting downstream activation of GNAQ have shown promise in mouse models of GNAQ-mutated uveal melanoma [30-32] and patients with these tumors have entered clinical trials (NCT01801358). This evidence concerns the gene GNAQ and Sturge-Weber syndrome.